We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sphere Fluidics selected as a finalist for 2018 Red Herring Top 100 Europe Award

Sphere Fluidics selected as a finalist for 2018 Red Herring Top 100 Europe Award content piece image
Cyto-Mine® Single Cell Analysis System
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced  it has been selected as a finalist for Red Herring's Top 100 Europe award, a prestigious list honoring the year’s most promising private technology ventures from the European business region.

Sphere Fluidics develops and manufactures the Cyto-Mine® Single Cell Analysis System, for use in biotherapeutic discovery and development. The Cyto-Mine, underpinned by the Company’s patented picodroplet technology, integrates selective screening of tens of millions of single cells, sorting, isolation and clone verification into a single automated platform. This streamlines workflows, reduces costs, improves throughput and enables high-value clones to be captured in a single run.

The Red Herring editorial team selects the most innovative companies from over 1,200 companies in the telecommunications, security, cloud, software, hardware, biotech, mobile and other industries across Europe. The nominees are then evaluated on 20 main quantitative and qualitative criteria, which include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries. This unique assessment of potential is complemented by a review of the track record and standing of a company.

Dr Frank Craig, CEO of Sphere Fluidics, said: “Sphere Fluidics’ proprietary picodroplet technology has enabled us to deliver a pioneering single cell analysis and monoclonality assurance system, the Cyto-Mine, for biotherapeutic discovery and development. We are delighted to have been recognized as an innovative company by Red Herring and shortlisted as a finalist for this year’s Top 100 Europe Award.”

"This year was rewarding, beyond all expectations" said Alex Vieux, publisher and CEO of Red Herring. "There are many great companies generating really innovative and disruptive products in Europe. We had a very difficult time narrowing the pool and selecting the finalists. Sphere Fluidics shows great promise and therefore deserves to be among the finalists. Now we’re faced with the difficult task of selecting the Top 100 winners of Red Herring Europe. We know that the 2018 crop will grow into some amazing companies that are sure to make an impact."